231 related articles for article (PubMed ID: 32434560)
1. Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
Vuolukka K; Auvinen P; Palmgren JE; Aaltomaa S; Kataja V
BMC Cancer; 2020 May; 20(1):453. PubMed ID: 32434560
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer.
Vuolukka K; Auvinen P; Palmgren JE; Voutilainen T; Aaltomaa S; Kataja V
Brachytherapy; 2019; 18(5):583-588. PubMed ID: 31227400
[TBL] [Abstract][Full Text] [Related]
3. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
4. Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy.
Nakai Y; Tanaka N; Asakawa I; Morizawa Y; Yamaki K; Hori S; Gotoh D; Miyake M; Torimoto K; Hasegawa M; Fujimoto K
Brachytherapy; 2022; 21(5):626-634. PubMed ID: 35644732
[TBL] [Abstract][Full Text] [Related]
5. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
6. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
7. The risk of second malignancies after
Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
[TBL] [Abstract][Full Text] [Related]
8. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
9. Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.
Chattopadhyay S; Hemminki O; Försti A; Sundquist K; Sundquist J; Hemminki K
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):143-149. PubMed ID: 30185889
[TBL] [Abstract][Full Text] [Related]
10. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
[TBL] [Abstract][Full Text] [Related]
11. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
12. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
13. Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis.
Hegemann NS; Schlesinger-Raab A; Ganswindt U; Hörl C; Combs SE; Hölzel D; Gschwend JE; Stief C; Belka C; Engel J
Radiat Oncol; 2017 Jan; 12(1):2. PubMed ID: 28049538
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
15. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
16. Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract][Full Text] [Related]
17. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model.
Takam R; Bezak E; Yeoh EE
Phys Med Biol; 2009 Feb; 54(3):611-25. PubMed ID: 19124952
[TBL] [Abstract][Full Text] [Related]
18. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
19. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.
Sung H; Hyun N; Leach CR; Yabroff KR; Jemal A
JAMA; 2020 Dec; 324(24):2521-2535. PubMed ID: 33351041
[TBL] [Abstract][Full Text] [Related]
20. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
